The Prognostic Value of Pentraxin-3 in COVID-19 Patients: A Systematic Review and Meta-Analysis of Mortality Incidence

Over the last three years, humanity has been facing one of the most serious health emergencies due to the global spread of Coronavirus disease (COVID-19). In this scenario, the research of reliable biomarkers of mortality from COVID-19 represents a primary objective. Pentraxin 3 (PTX3), a highly con...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-02, Vol.24 (4), p.3537
Main Authors: Capra, Anna Paola, Ardizzone, Alessio, Pantò, Giuseppe, Paterniti, Irene, Campolo, Michela, Crupi, Lelio, Squeri, Raffaele, Esposito, Emanuela
Format: Article
Language:English
Subjects:
Analysis
B cells
Biomarkers - metabolism
C-Reactive Protein - metabolism
Coronaviruses
COVID-19
COVID-19 - metabolism
COVID-19 - mortality
COVID-19 vaccines
Cytokines
Death
Humans
Immunology
immunopathology
Infections
Innate immunity
Mediation
Medical research
Medicine, Experimental
Meta-analysis
Mortality
Pandemics
Pathogens
Pentraxin-3 (PTX3)
Pentraxins
Prognosis
Review
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the last three years, humanity has been facing one of the most serious health emergencies due to the global spread of Coronavirus disease (COVID-19). In this scenario, the research of reliable biomarkers of mortality from COVID-19 represents a primary objective. Pentraxin 3 (PTX3), a highly conserved protein of innate immunity, seems to be associated with a worse outcome of the disease. Based on the above, this systematic review and meta-analysis evaluated the prognostic potential of PTX3 in COVID-19 disease. We included 12 clinical studies evaluating PTX3 in COVID-19 patients. From our research, we found increased PTX3 levels compared to healthy subjects, and notably, PTX3 was even more augmented in severe COVID-19 rather than non-severe cases. Moreover, we performed a meta-analysis to establish if there were differences between ICU and non-ICU COVID-19 patients in PTX3-related death. We combined 5 studies for a total of 543 ICU vs. 515 non-ICU patients. We found high significative PTX3-related death in ICU COVID-19 hospitalized individuals (184 out of 543) compared to non-ICU (37 out of 515), with an overall effect OR: 11.30 [2.00, 63.73]; = 0.006. In conclusion, we probed PTX3 as a reliable marker of poor outcomes after COVID-19 infection as well as a predictor of hospitalized patients' stratification.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24043537